ABSTRACT
Invasive fungal infections (IFIs) occur in most immunocompromised patients such as the neutropenic patient undergoing chemotherapy for hematologic malignancy (HM) and the recipients of hematopoietic cell transplantation (HCT) or solid organ transplantation (SOT). While invasive mold infections (IMIs), predominantly invasive aspergillosis (IA), occur only in severely immunocompromised hosts, invasive candidiasis (IC) occurs in severely ill, non-immunocompromised patients.
